Centers For Medicare & Medicaid Services Extends Coverage Of Natera's Signatera Molecular Residual Disease Test To Ovarian Cancer And Neoadjuvant Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
The Centers For Medicare & Medicaid Services (CMS) has expanded coverage for Natera's Signatera Molecular Residual Disease Test to include ovarian cancer and neoadjuvant breast cancer. This decision broadens the potential patient base for Natera's diagnostic test, potentially increasing its usage and revenue from these additional cancer types.
February 26, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CMS's decision to extend coverage for Natera's Signatera Test to ovarian and neoadjuvant breast cancer could significantly increase its market reach and revenue.
The extension of CMS coverage for Natera's Signatera Test to additional cancer types directly impacts Natera by potentially increasing the usage of its diagnostic test. This could lead to higher revenue from increased market reach and validates the clinical utility of the test in a broader range of cancers.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90